Induction of apoptosis in endometrial cancer cells by psammaplysene A involves FOXO1

Gynecologic Oncology

Volumn 112, Issue 2, 2009, Pages 331-336

  Berry, Emily ^a   Hardt, Jennifer L ^a   Clardy, Jon ^b   Lurain, John R ^a   Kim, J Julie ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AKT; Endometrial cancer; FOXO1

Indexed keywords

BROXURIDINE; PSAMMAPLYSENE A; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

ADENOVIRUS; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SPONGE (PORIFERA);

APOPTOSIS; CELL DIVISION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL NUCLEUS; ENDOMETRIAL NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; G2 PHASE; HUMANS; RNA, SMALL INTERFERING; TRANSFECTION; TYROSINE;

EID: 58149490950     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.10.017     Document Type: Article

References (39)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. C.A. Cancer J. Clin. 58 (2008) 71-96
2. Fanning J., Evans M.C., Peters A.J., Samuel M., Harmon E.R., and Bates J.S. Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile. Gynecol. Oncol. 32 (1989) 288-291
3. Tashiro H., Blazes M.S., Wu R., Cho K.R., Bose S., Wang S.I., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57 (1997) 3935-3940
4. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005) 988-1004
5. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
6. Biggs III W.H., Meisenhelder J., Hunter T., Cavenee W.K., and Arden K.C. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7421-7426
7. Huang H., and Tindall D.J. FOXO factors: a matter of life and death. Future Oncol. 2 (2006) 83-89
8. Alikhani M., Alikhani Z., and Graves D.T. FOXO1 functions as a master switch that regulates gene expression necessary for tumor necrosis factor-induced fibroblast apoptosis. J. Biol. Chem. 280 (2005) 12096-12102
9. Accili D., and Arden K.C. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117 (2004) 421-426
10. Burgering B.M., and Kops G.J. Cell cycle and death control: long live Forkheads. Trends Biochem. Sci. 27 (2002) 352-360
11. Ward E.C., Hoekstra A.V., Blok L.J., Hanifi-Moghaddam P., Lurain J.R., Singh D.K., et al. The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology 149 (2008) 1942-1950
12. Goto T., Takano M., Albergaria A., Briese J., Pomeranz K.M., Cloke B., et al. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 27 (2008) 9-19
13. Huang H., Regan K.M., Wang F., Wang D., Smith D.I., van Deursen J.M., et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1649-1654
14. Hoekstra A.V., Ward E.C., Hardt J.L., Lurain J.R., Singh D.K., Buttin B.M., et al. Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecol. Oncol. 108 (2008) 609-618
15. Kau T.R., Schroeder F., Ramaswamy S., Wojciechowski C.L., Zhao J.J., Roberts T.M., et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4 (2003) 463-476
16. Schroeder F.C., Kau T.R., Silver P.A., and Clardy J. The psammaplysenes, specific inhibitors of FOXO1a nuclear export. J. Nat. Prod. 68 (2005) 574-576
17. Georgiades S.N., and Clardy J. Total synthesis of psammaplysenes A and B, naturally occurring inhibitors of FOXO1a nuclear export. Org. Lett. 7 (2005) 4091-4094
18. Georgiades S.N., and Clardy J. Preparation of a psammaplysene-based library. Org. Lett. 8 (2006) 4251-4254
19. Nishida M., Kasahara K., Kaneko M., Iwasaki H., and Hayashi K. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Gakkai Zasshi 37 (1985) 1103-1111
20. Hata H., Holinka C.F., Pahuja S.L., Hochberg R.B., Kuramoto H., and Gurpide E. Estradiol metabolism in Ishikawa endometrial cancer cells. J. Steroid. Biochem. 26 (1987) 699-704
21. Croxtall J.D., Elder M.G., and White J.O. Hormonal control of proliferation in the Ishikawa endometrial adenocarcinoma cell line. J. Steroid. Biochem. 35 (1990) 665-669
22. Lessey B.A., Ilesanmi A.O., Castelbaum A.J., Yuan L., Somkuti S.G., Chwalisz K., et al. Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone-induced expression of the alpha1 integrin. J. Steroid. Biochem. Mol. Biol. 59 (1996) 31-39
23. Castelbaum A.J., Ying L., Somkuti S.G., Sun J., Ilesanmi A.O., and Lessey B.A. Characterization of integrin expression in a well differentiated endometrial adenocarcinoma cell line (Ishikawa). J. Clin. Endocrinol. Metab. 82 (1997) 136-142
24. Lovely L.P., Appa Rao K.B., Gui Y., and Lessey B.A. Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa). J. Steroid. Biochem. Mol. Biol. 74 (2000) 235-241
25. Satyaswaroop P.G., Zaino R.J., and Mortel R. Human endometrial adenocarcinoma transplanted into nude mice: growth regulation by estradiol. Science 219 (1983) 58-60
26. Mo B., Vendrov A.E., Palomino W.A., DuPont B.R., Apparao K.B., and Lessey B.A. ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium. Biol. Reprod. 75 (2006) 387-394
27. Jin X., Gossett D.R., Wang S., Yang D., Cao Y., Chen J., et al. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br. J. Cancer 91 (2004) 1808-1812
28. Zhou C., Gehrig P.A., Whang Y.E., and Boggess J.F. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol. Cancer Ther. 2 (2003) 789-795
29. Barr F.G. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 20 (2001) 5736-5746
30. Modur V., Nagarajan R., Evers B.M., and Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J. Biol. Chem. 277 (2002) 47928-47937
31. Sunters A., Fernandez de Mattos S., Stahl M., Brosens J.J., Zoumpoulidou G., Saunders C.A., et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem. 278 (2003) 49795-49805
32. Park Y., Liu Y., Hong J., Lee C.O., Cho H., Kim D.K., et al. New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis. J. Nat. Prod. 66 (2003) 1495-1498
33. Kim D., Lee I.S., Jung J.H., Lee C.O., and Choi S.U. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells. Anticancer Res. 19 (1999) 4085-4090
34. Nicholas G.M., Eckman L.L., Ray S., Hughes R.O., Pfefferkorn J.A., Barluenga S., et al. Bromotyrosine-derived natural and synthetic products as inhibitors of mycothiol-S-conjugate amidase. Bioorg. Med. Chem. Lett. 12 (2002) 2487-2490
35. Tabudravu J.N., Eijsink V.G., Gooday G.W., Jaspars M., Komander D., Legg M., et al. Psammaplin A, a chitinase inhibitor isolated from the Fijian marine sponge Aplysinella rhax. Bioorg. Med. Chem. 10 (2002) 1123-1128
36. Shim J.S., Lee H.S., Shin J., and Kwon H.J. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett. 203 (2004) 163-169
37. Kim D.H., Shin J., and Kwon H.J. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp. Mol. Med. 39 (2007) 47-55
38. Pina I.C., Gautschi J.T., Wang G.Y., Sanders M.L., Schmitz F.J., France D., et al. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem. 68 (2003) 3866-3873
39. Ahn M.Y., Jung J.H., Na Y.J., and Kim H.S. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol. Oncol. 108 (2008) 27-33